Thrivent Financial For Lutherans raised its stake in Prothena Corporation PLC (NASDAQ:PRTA) by 15.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 37,170 shares of the biotechnology company’s stock after buying an additional 5,070 shares during the period. Thrivent Financial For Lutherans owned about 0.11% of Prothena Corporation PLC worth $2,074,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of PRTA. Victory Capital Management Inc. purchased a new position in Prothena Corporation PLC during the first quarter worth about $588,000. OMERS ADMINISTRATION Corp purchased a new position in Prothena Corporation PLC during the first quarter worth about $273,000. Russell Investments Group Ltd. purchased a new position in Prothena Corporation PLC during the fourth quarter worth about $528,000. American International Group Inc. boosted its position in Prothena Corporation PLC by 5.3% in the first quarter. American International Group Inc. now owns 21,039 shares of the biotechnology company’s stock worth $1,174,000 after buying an additional 1,066 shares during the last quarter. Finally, Ameritas Investment Partners Inc. purchased a new position in Prothena Corporation PLC during the first quarter worth about $167,000.
Shares of Prothena Corporation PLC (PRTA) opened at 64.65 on Tuesday. The stock’s market cap is $2.46 billion. The company has a 50 day moving average price of $53.94 and a 200 day moving average price of $52.72. Prothena Corporation PLC has a 1-year low of $40.58 and a 1-year high of $68.18.
Prothena Corporation PLC (NASDAQ:PRTA) last issued its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.33. The business had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.26 million. Prothena Corporation PLC had a negative return on equity of 39.67% and a negative net margin of 16,012.49%. The business’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.81) earnings per share. On average, equities analysts anticipate that Prothena Corporation PLC will post ($4.76) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Thrivent Financial For Lutherans Acquires 5,070 Shares of Prothena Corporation PLC (NASDAQ:PRTA)” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.chaffeybreeze.com/2017/07/18/prothena-corporation-plc-prta-shares-bought-by-thrivent-financial-for-lutherans-updated-updated.html.
A number of equities research analysts have recently weighed in on the company. ValuEngine lowered Prothena Corporation PLC from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 27th. Zacks Investment Research lowered Prothena Corporation PLC from a “buy” rating to a “hold” rating in a research note on Monday, May 15th. Oppenheimer Holdings, Inc. set a $70.00 target price on Prothena Corporation PLC and gave the company a “buy” rating in a research note on Thursday, May 11th. Wedbush reaffirmed an “outperform” rating and set a $77.00 price target on shares of Prothena Corporation PLC in a research report on Monday, April 3rd. Finally, Jefferies Group LLC initiated coverage on Prothena Corporation PLC in a research report on Monday, July 10th. They set a “buy” rating and a $100.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $77.07.
In other news, Director Dennis J. Selkoe sold 3,500 shares of the company’s stock in a transaction on Friday, July 7th. The stock was sold at an average price of $58.11, for a total transaction of $203,385.00. Following the transaction, the director now directly owns 6,345 shares of the company’s stock, valued at $368,707.95. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 3.10% of the company’s stock.
About Prothena Corporation PLC
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.